DR. JOHN THOMAS BRANDT, M.D.
Medical Practice at Royal Oakland Dr, Indianapolis, IN
License number
Indiana 01050305A
Category
Medical Practice
Type
Hematology
License number
Indiana 01050305A
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
7330 Royal Oakland Dr, Indianapolis, IN 46236
Phone
(317) 823-0575
Personal information
See more information about JOHN THOMAS BRANDT at radaris.comName
Address
Phone
62201 Ash Rd, Wakarusa, IN 46573
3910 Kitty Hawk Ct, Carmel, IN 46033
8062 450 S, West Lebanon, IN 47991
Professional information
See more information about JOHN THOMAS BRANDT at trustoria.com
Dr. John T Brandt, Indianapolis IN - MD (Doctor of Medicine)
Dr. John T Brandt, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Hematology, Hematopathology
Address:
7330 Royal Oakland Dr, Indianapolis 46236
(317) 823-0575 (Phone)
(317) 823-0575 (Phone)
Certifications:
Anatomic & Clinical Pathology, 1980, Hematology & Pathology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Missouri / Columbia Campus
Graduated: 1976
The Ohio State University Hospitals
Iu Health Ball Memorial
University of Missouri / Columbia Campus
Graduated: 1976
The Ohio State University Hospitals
Iu Health Ball Memorial
Human Stem Cell Compositions And Methods
Human Stem Cell Compositions And Methods
US Patent:
5672346, Sep 30, 1997
Filed:
Jun 15, 1993
Appl. No.:
8/077134
Inventors:
Edward Srour - Indianapolis IN
Esmail Zanjani - Reno NV
John E. Brandt - Indianapolis IN
Ronald Hoffman - Indianapolis IN
Esmail Zanjani - Reno NV
John E. Brandt - Indianapolis IN
Ronald Hoffman - Indianapolis IN
Assignee:
Indiana University Foundation - Bloomington IN
International Classification:
A61K 3514
US Classification:
424 937
Abstract:
Disclosed are human pluripotent hematopoietic stem cell (PHSC) enriched compositions and methods for obtaining and using the compositions. A substantially homogeneous population of human hematopoietic cells characterized as CD34. sup. +, HLA-DR. sup. -, and c-kit receptor positive (KR. sup. +) and capable of in vitro self-renewal and differentiation to members of at least the erythroid, myeloid, and megakaryocytic lineages, is obtained by separating the population from a cellular mixture, for example by cytometric cell sorting techniques. Also disclosed is a method of obtaining persistent maintenance of grafted human hematopoietic cells in a mammal, which includes grafting a mammal in utero with a cellular composition enriched in human hematopoietic cells characterized as CD34. sup. +, HLA-DR. sup. - and capable of in vitro self-renewal and differentiation to members of the lymphoid, myeloid, erythroid and megakaryocytic lineages.
Retired At Wenatchee, Wa
Retired At Wenatchee, Wa
Position:
Retired at Wenatchee, WA
Location:
Indianapolis, Indiana Area
Industry:
Pharmaceuticals
Work:
Wenatchee, WA
- Wenatchee, WA since Apr 2012
-
Retired
Eli Lilly
Jan 1999 - Mar 2012
-
Senior Medical Fellow
Method For Treating Cardiovascular Diseases
Method For Treating Cardiovascular Diseases
US Patent:
2006021, Sep 28, 2006
Filed:
Apr 26, 2004
Appl. No.:
10/553763
Inventors:
John Brandt - Indianapolis IN, US
Nagy Farid - Lebanon IN, US
Joseph Jakubowski - Indianapolis IN, US
Kenneth Winters - Germantown TN, US
Nagy Farid - Lebanon IN, US
Joseph Jakubowski - Indianapolis IN, US
Kenneth Winters - Germantown TN, US
International Classification:
A61K 31/4743, A61K 31/60, A61H 1/00
US Classification:
514165000, 514301000, 601001000
Abstract:
A method of treating Cardiovascular Diseases comprising administering of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, prodrug, active metabolite, racemate or enantiomer thereof, in conjunction with coronary and non-coronary intervention procedures is disclosed.
Expansion Of Human Hematopoietic Progenitor Cells In A Liquid Medium
Expansion Of Human Hematopoietic Progenitor Cells In A Liquid Medium
US Patent:
5409825, Apr 25, 1995
Filed:
Oct 12, 1993
Appl. No.:
8/133093
Inventors:
Ronald Hoffman - Indianapolis IN
John Brandt - Indianapolis IN
John Brandt - Indianapolis IN
International Classification:
C12N 500, C12N 502, C12N 508
US Classification:
4352401
Abstract:
A process for supporting hematopoietic progenitor cells in a culture medium which contains at least one cytokine effective for supporting the cells, and preferably, is essentially free of stromal cells.
Dosage Regimen For Prasugrel
Dosage Regimen For Prasugrel
US Patent:
2009015, Jun 18, 2009
Filed:
Jun 13, 2006
Appl. No.:
11/916817
Inventors:
John Thomas Brandt - Indianapolis IN, US
Nagy Alphonse Farid - Lebanon IN, US
Joseph Anthony Jakubowski - Indianapolis IN, US
Christopher David Payne - Hampshire, GB
Govinda Jayanath Weerakkody - Carmel IN, US
Kenneth John Winters - Memphis TN, US
Nagy Alphonse Farid - Lebanon IN, US
Joseph Anthony Jakubowski - Indianapolis IN, US
Christopher David Payne - Hampshire, GB
Govinda Jayanath Weerakkody - Carmel IN, US
Kenneth John Winters - Memphis TN, US
International Classification:
A61K 31/4365, A61P 9/00
US Classification:
514301
Abstract:
A dosage regimen for treating vascular disease in a human comprising the steps of administering a loading dosage of about 30 mg to 70 mg of loading dose of prasugrel or a pharmaceutically acceptable salt thereof, and thereafter administering a daily dosage regimen of about 7.5 mg to 15 mg maintenance dose of prasugrel or a pharmaceutically acceptable salt thereof.
Use Of Par-1/Par-4 Inhibitors For Treating Or Preventing Vascular Diseases
Use Of Par-1/Par-4 Inhibitors For Treating Or Preventing Vascular Diseases
US Patent:
2008021, Sep 4, 2008
Filed:
Aug 8, 2006
Appl. No.:
11/996380
Inventors:
John Thomas Brandt - Indianapolis IN, US
Victor Leonid Serebruany - West Friendship MD, US
Kenneth John Winters - Memphis TN, US
Victor Leonid Serebruany - West Friendship MD, US
Kenneth John Winters - Memphis TN, US
International Classification:
A61K 31/4365, A61P 3/00, A61P 9/00
US Classification:
514301
Abstract:
Use of a compound of formula (I) or a compound selected from the group consisting of a prasugrel metabolite, clopidogrel, a clopidogrel metabolite, ticlopidine, a ticlopidine metabolite, cangrelor, a cangrelor metabolite, AZD-6140, and an AZD-6140 metabolite for the treatment of and/or prevention of coagulation induced vascular diseases and recurrence thereof in a patient in need thereof.